Information Provided By:
Fly News Breaks for May 7, 2015
REGN
May 7, 2015 | 13:51 EDT
BofA/Merrill said Regeneron's Eylea continues to gain U.S. market share from Avastin and Lucentis. As a result, the firm increased 2015 U.S. Eylea sales estimate to $2.33B from $2.24B and increased its price target to $518 from $466. Shares or Regeneron are Buy rated.
News For REGN From the Last 2 Days
There are no results for your query REGN